Personalis Stock Price, News & Analysis

Personalis, Inc. (NASDAQ: PSNL) has partnered with Duke University and Olink Proteomics AB to research the effects of immunotherapy on advanced gastroesophageal cancer. The collaboration aims to identify composite biomarkers to enhance therapeutic decision-making. Gastroesophageal cancer is prevalent, with nearly 50% of patients facing advanced stages at diagnosis. Key goals include understanding responses to pembrolizumab, an approved immunotherapy, and developing strategies to optimize treatment effectiveness. The study will leverage Personalis' cutting-edge technology for comprehensive tumor profiling.

On September 13, 2022, at 1:30 p.m. Eastern Time, Personalis, Inc. (NASDAQ: PSNL) will present at the Morgan Stanley 20th Annual Global Healthcare Conference in New York, NY. As a leader in advanced cancer genomics, Personalis offers innovative solutions for precision cancer therapies and diagnostics through its Personalis NeXT Platform. The company's Clinical Laboratory is recognized for its accuracy, quality, and efficiency, complying with industry standards.

Personalis, Inc. (NASDAQ: PSNL) announced the filing of an amended complaint against Foresight Diagnostics, claiming infringement of its newly issued US Patent No. 11,408,033. This patent strengthens Personalis' position in the molecular residual disease (MRD) testing space. The patent enables personalized MRD panels, utilizing tumor-informed and database-derived content for enhanced cancer detection. Personalis seeks injunctive relief and damages from Foresight’s alleged infringement, reinforcing its commitment to protect its intellectual property as it expands its advanced cancer genomics capabilities.

Personalis, Inc. (NASDAQ: PSNL) announced on August 15, 2022, that its Compensation Committee granted non-qualified stock options and restricted stock units (RSUs) totaling 70,000 shares each to two new employees under its 2020 Inducement Plan. The stock options have an exercise price of $5.32 per share, aligning with the closing stock price on the grant date. Vested options and RSUs will occur over four years. This grant complies with Nasdaq rules and is aimed at attracting talent to enhance the company's growth in advanced cancer genomics.

Personalis has announced a collaboration with BC Cancer to implement the NeXT Personal liquid biopsy assay in a study focused on colorectal and pancreatic cancers. This personalized assay aims to enhance molecular residual disease (MRD) detection by analyzing circulating tumor DNA (ctDNA) from blood samples. The study will enroll approximately 220 patients across British Columbia and seek to evaluate cost-effectiveness compared to traditional imaging methods. Insights from this research could significantly impact cancer management and patient survival.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced cancer genomics, announced its participation in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on August 16, 2022. This event will feature the management team discussing innovations in precision cancer therapies and diagnostics through the Personalis NeXT Platform, which analyzes the full spectrum of human genes and immune system data.

Personalis' Clinical Laboratory is GxP-aligned and certified, emphasizing clinical accuracy and efficiency.

Personalis, Inc. (PSNL) reported Q2 2022 results, with revenues of $18.2 million, down from $21.7 million in Q2 2021. Revenue from biopharma customers rose by 74% to $14.2 million, boosted by $6.8 million from Natera. VA MVP revenues fell sharply to $4.0 million from $13.5 million year-over-year. The company incurred a net loss of $27.5 million and anticipates total 2022 revenues between $62.0 million to $67.0 million. Notably, cash reserves were strong at $233.5 million as of June 30, 2022.

Personalis, Inc. (Nasdaq: PSNL) has filed a lawsuit against Foresight Diagnostics Inc. for infringing its U.S. Patent Nos. 10,450,611, 11,299,783, and 11,384,394, central to its tumor-informed molecular residual disease (MRD) testing innovations. This legal action seeks both injunctive relief and monetary damages. Personalis emphasizes its long-standing expertise in whole genome sequencing, asserting that its NeXT Personal MRD solution represents a significant advancement in cancer detection, achieving unmatched sensitivity in identifying residual cancer cells.

Personalis, Inc. (NASDAQ: PSNL) will release its second quarter 2022 financial results on August 3, 2022. The company will also host a conference call and webcast at 2:00 p.m. PT to discuss financial outcomes and recent developments. Interested participants can register for the call via the provided link and access the live webinar on the company's website. Personalis is recognized for its advancements in cancer genomics, playing a pivotal role in precision oncology through the Personalis NeXT Platform®.